Active Ingredient History
Fulvestrant is a drug treatment of hormone receptor-positive metastatic breast cancer in post-menopausal women with disease progression following anti-estrogen therapy. It is an estrogen receptor antagonist with no agonist effects, which works both by down-regulating and by degrading the estrogen receptor. Fulvestrant competitively and reversibly binds to estrogen receptors present in cancer cells and achieves its anti-estrogen effects through two separate mechanisms. First, fulvestrant binds to the receptors and downregulates them so that estrogen is no longer able to bind to these receptors. Second, fulvestrant degrades the estrogen receptors to which it is bound. Both of these mechanisms inhibit the growth of tamoxifen-resistant as well as estrogen-sensitive human breast cancer cell lines. Fulvestrant is used for the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy. Fulvestrant is marketed under the trade name Faslodex, by AstraZeneca. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Adenocarcinoma of Lung (Phase 1)
Adenosarcoma (Phase 2)
Biliary Tract Neoplasms (Phase 2)
Brain Neoplasms (Phase 2)
BRCA1 Protein (Phase 1)
Carcinoma, Ductal, Breast (Phase 1/Phase 2)
Carcinoma, Intraductal, Noninfiltrating (Phase 2)
Carcinoma, Non-Small-Cell Lung (Phase 2)
Carcinoma, Ovarian Epithelial (Phase 1)
Carcinoma, Transitional Cell (Phase 1/Phase 2)
Carcinosarcoma (Phase 1/Phase 2)
Colorectal Neoplasms (Phase 1)
Endometrial Neoplasms (Phase 2)
Esophageal Neoplasms (Phase 1/Phase 2)
Fallopian Tube Neoplasms (Phase 2)
Fibrous Dysplasia, Polyostotic (Phase 2)
Gene Amplification (Phase 1/Phase 2)
Genetic Diseases, Inborn (Phase 2)
Genital Neoplasms, Female (Phase 1/Phase 2)
Hamartoma (Phase 2)
Head and Neck Neoplasms (Phase 2)
Healthy Volunteers (Phase 1)
Leiomyosarcoma (Phase 2)
Liposarcoma (Phase 1)
Lung Neoplasms (Phase 2)
Lupus Erythematosus, Systemic (Phase 2)
Lymphoma, Non-Hodgkin (Phase 1)
Mesothelioma, Malignant (Phase 1)
Mutation (Phase 2)
Neoadjuvant Therapy (Phase 2/Phase 3)
Neoplasm Metastasis (Phase 4)
Neoplasms ()
Ovarian Neoplasms (Phase 2)
Pancreatic Neoplasms (Phase 2)
Pharmacokinetics (Phase 1/Phase 2)
Postmenopause (Phase 2)
Progression-Free Survival (Phase 3)
Prostatic Neoplasms (Phase 2)
Puberty, Precocious (Phase 2)
Pulmonary Arterial Hypertension (Phase 2)
Quality of Life (Phase 2)
Receptors, Fibroblast Growth Factor (Phase 2)
Recurrence (Phase 2)
Sarcoma (Phase 2)
Sarcoma, Endometrial Stromal (Phase 2)
Sex Cord-Gonadal Stromal Tumors (Phase 2)
Squamous Cell Carcinoma of Head and Neck (Phase 1/Phase 2)
Stomach Neoplasms (Phase 2)
Triple Negative Breast Neoplasms (Phase 2)
Urologic Neoplasms (Phase 2)
Uterine Cervical Neoplasms (Phase 2)
Uterine Neoplasms (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
